The latest financial statement is for the quarter ending 2025-06-30.
| Cash Flow | 2025-06-30 |
|---|---|
| Share-based payments | 3,240,107 |
| Net loss for the period | -18,909,992 |
| Amortization of right-of-use asset | 63,836 |
| Accrued investment income | -89,126 |
| Receivables | 112,456 |
| Prepaids | -286,517 |
| Operating lease liability | -85,796 |
| Accounts payable and accrued liabilities | -1,577,018 |
| Accretion of lease liability | 19,819 |
| Accretion of premiums/discounts on short-term investments, net | 501,314 |
| Termination of lease (note 7) | 31,648 |
| Net cash used in operating activities | -17,518,819 |
| Proceeds from short-term investments sold | 29,225,000 |
| Purchase of short-term investments | 29,463,131 |
| Net cash provided by (used in) investing activities | -238,131 |
| Options exercised | 0 |
| Shares purchased through employee share purchase plan | 0 |
| Net cash provided by financing activities | 0 |
| Effect of foreign exchange on cash and cash equivalents | 0 |
| Change in cash and cash equivalents for the period | -17,756,950 |
ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. (EPIX)